Annual CFI
-$223.62 M
-$159.80 M-250.37%
December 31, 2023
Summary
- As of February 7, 2025, AKRO annual cash flow from investing activities is -$223.62 million, with the most recent change of -$159.80 million (-250.37%) on December 31, 2023.
- During the last 3 years, AKRO annual CFI has fallen by -$213.86 million (-2190.98%).
- AKRO annual CFI is now -628.91% below its all-time high of $42.28 million, reached on December 31, 2021.
Performance
AKRO Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$73.07 M
+$328.96 M+128.55%
September 30, 2024
Summary
- As of February 7, 2025, AKRO quarterly cash flow from investing activities is $73.07 million, with the most recent change of +$328.96 million (+128.55%) on September 30, 2024.
- Over the past year, AKRO quarterly CFI has increased by +$198.76 million (+158.13%).
- AKRO quarterly CFI is now at all-time high.
Performance
AKRO Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$112.19 M
+$198.76 M+63.92%
September 30, 2024
Summary
- As of February 7, 2025, AKRO TTM cash flow from investing activities is -$112.19 million, with the most recent change of +$198.76 million (+63.92%) on September 30, 2024.
- Over the past year, AKRO TTM CFI has increased by +$225.66 million (+66.79%).
- AKRO TTM CFI is now -263.66% below its all-time high of $68.55 million, reached on June 30, 2022.
Performance
AKRO TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
AKRO Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -250.4% | +158.1% | +66.8% |
| 3 y3 years | -2191.0% | +233.1% | -332.9% |
| 5 y5 years | -4372.5% | +100.0% | -56.9% |
AKRO Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -628.9% | at low | at high | +128.6% | -263.7% | +66.8% |
| 5 y | 5-year | -628.9% | at low | at high | +128.6% | -263.7% | +66.8% |
| alltime | all time | -628.9% | at low | at high | +128.6% | -263.7% | +66.8% |
Akero Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $73.07 M(-128.6%) | -$112.19 M(-63.9%) |
| Jun 2024 | - | -$255.90 M(-542.4%) | -$310.96 M(+69.6%) |
| Mar 2024 | - | $57.85 M(+352.4%) | -$183.36 M(-18.0%) |
| Dec 2023 | -$223.62 M(+250.4%) | $12.79 M(-110.2%) | -$223.62 M(-33.8%) |
| Sep 2023 | - | -$125.70 M(-2.0%) | -$337.85 M(+61.5%) |
| Jun 2023 | - | -$128.30 M(-829.4%) | -$209.16 M(+203.2%) |
| Mar 2023 | - | $17.59 M(-117.3%) | -$68.98 M(+8.1%) |
| Dec 2022 | -$63.83 M(-251.0%) | -$101.44 M(-3481.5%) | -$63.83 M(-228.6%) |
| Sep 2022 | - | $3.00 M(-74.7%) | $49.62 M(-27.6%) |
| Jun 2022 | - | $11.87 M(-47.8%) | $68.55 M(+48.9%) |
| Mar 2022 | - | $22.75 M(+89.6%) | $46.03 M(+8.9%) |
| Dec 2021 | $42.28 M | $12.00 M(-45.3%) | $42.28 M(-12.2%) |
| Sep 2021 | - | $21.93 M(-305.9%) | $48.18 M(-243.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$10.65 M(-156.1%) | -$33.60 M(-316.5%) |
| Mar 2021 | - | $19.00 M(+6.2%) | $15.52 M(-259.0%) |
| Dec 2020 | -$9.76 M(-86.4%) | $17.90 M(-129.9%) | -$9.76 M(-90.2%) |
| Sep 2020 | - | -$59.84 M(-255.6%) | -$99.17 M(+152.2%) |
| Jun 2020 | - | $38.47 M(-712.4%) | -$39.33 M(-49.4%) |
| Mar 2020 | - | -$6.28 M(-91.2%) | -$77.79 M(+8.8%) |
| Dec 2019 | -$71.51 M(+1330.3%) | -$71.51 M(<-9900.0%) | -$71.51 M(<-9900.0%) |
| Sep 2019 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2019 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2019 | - | $0.00(0.0%) | -$5.00 M(0.0%) |
| Dec 2018 | -$5.00 M | $0.00(0.0%) | -$5.00 M(0.0%) |
| Sep 2018 | - | $0.00(-100.0%) | -$5.00 M(0.0%) |
| Jun 2018 | - | -$5.00 M | -$5.00 M |
FAQ
- What is Akero Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Akero Therapeutics?
- What is Akero Therapeutics annual CFI year-on-year change?
- What is Akero Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Akero Therapeutics?
- What is Akero Therapeutics quarterly CFI year-on-year change?
- What is Akero Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Akero Therapeutics?
- What is Akero Therapeutics TTM CFI year-on-year change?
What is Akero Therapeutics annual cash flow from investing activities?
The current annual CFI of AKRO is -$223.62 M
What is the all time high annual CFI for Akero Therapeutics?
Akero Therapeutics all-time high annual cash flow from investing activities is $42.28 M
What is Akero Therapeutics annual CFI year-on-year change?
Over the past year, AKRO annual cash flow from investing activities has changed by -$159.80 M (-250.37%)
What is Akero Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of AKRO is $73.07 M
What is the all time high quarterly CFI for Akero Therapeutics?
Akero Therapeutics all-time high quarterly cash flow from investing activities is $73.07 M
What is Akero Therapeutics quarterly CFI year-on-year change?
Over the past year, AKRO quarterly cash flow from investing activities has changed by +$198.76 M (+158.13%)
What is Akero Therapeutics TTM cash flow from investing activities?
The current TTM CFI of AKRO is -$112.19 M
What is the all time high TTM CFI for Akero Therapeutics?
Akero Therapeutics all-time high TTM cash flow from investing activities is $68.55 M
What is Akero Therapeutics TTM CFI year-on-year change?
Over the past year, AKRO TTM cash flow from investing activities has changed by +$225.66 M (+66.79%)